en
Scientific article
English

Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study

Published inThe Lancet, vol. 396, no. 10247, p. 313-319
Publication date2020
Abstract

Assessing the burden of COVID-19 on the basis of medically attended case numbers is suboptimal given its reliance on testing strategy, changing case definitions, and disease presentation. Population-based serosurveys measuring anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) antibodies provide one method for estimating infection rates and monitoring the progression of the epidemic. Here, we estimate weekly seroprevalence of anti-SARS-CoV-2 antibodies in the population of Geneva, Switzerland, during the epidemic.

Keywords
  • Adolescent
  • Adult
  • Age Distribution
  • Aged
  • Antibodies
  • Viral/blood
  • Betacoronavirus/immunology
  • Child
  • Child Preschool
  • Coronavirus Infections/epidemiology/virology
  • Female
  • Humans
  • Immunoglobulin G/blood
  • Male
  • Middle Aged
  • Pandemics
  • Pneumonia
  • Viral/epidemiology/virology
  • Prevalence
  • Seroepidemiologic Studies
  • Sex Distribution
  • Switzerland/epidemiology
  • Young Adult
Citation (ISO format)
STRINGHINI, Silvia et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. In: The Lancet, 2020, vol. 396, n° 10247, p. 313–319. doi: 10.1016/S0140-6736(20)31304-0
Main files (1)
Article (Published version)
accessLevelRestricted
Secondary files (1)
Identifiers
ISSN of the journal0140-6736
551views
14downloads

Technical informations

Creation08/20/2020 2:03:00 PM
First validation08/20/2020 2:03:00 PM
Update time03/15/2023 10:27:36 PM
Status update03/15/2023 10:27:35 PM
Last indexation08/30/2023 11:21:40 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack